Johnson & Johnson's nipocalimab improves Sjögren's disease activity in Phase 2 study, showing a 70% relative average improvement over placebo.
Johnson & Johnson's nipocalimab improves Sjögren's disease activity in Phase 2 study, demonstrating a 70% relative average improvement over placebo. This marks the first positive results for an advanced treatment in the chronic autoantibody disease with no current approved options. Late-breaking results show significant improvement in ClinESSDAI score at 24 weeks compared to baseline.
June 15, 2024
3 Articles